Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
- Conditions
- Nodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Grade 2 Follicular LymphomaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00275080
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
🇨🇦Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT00260065
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
- Conditions
- Interventions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00114257
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
- Conditions
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00113321
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00109824
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Decitabine in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00095784
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Oncology Care Associates PLLC, Saint Joseph, Michigan, United States
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- California Cancer Consortium
- Registration Number
- NCT00002980
- Locations
- 🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00089089
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00002832
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00084981
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.